Evaluation of OP-1 as a Graft Substitute for Intertransverse Process Lumbar Fusion

Grauer, Jonathan N.; Patel, Tushar; Erulkar, Jonathan S.; Troiano, Nancy; Panjabi, Manohar M.; Friedlaender, Gary E.

doi:10.1097/00007632-200101150-00004

Cited by 162 publications

(75 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Many studies have examined the effect of exogenous application of a single osteoinductive protein or growth factor to enhance bone repair and regeneration [6,7,14,23]. A potential alternative to the exogenous application of a single factor is a system designed to deliver the cells that have the factors themselves to the desired site.…”

Section: Introductionmentioning

confidence: 99%

Spinal fusion using an autologous growth factor gel and a porous resorbable ceramic

et al. 2004

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Spinal fusion using an autologous growth factor gel and a porous resorbable ceramic

et al. 2004

View full text Add to dashboard Cite

“…Because fusion rates of 100% have been seen consistently with OP-1 in this model [8], powered fusion analysis was not a primary objective. Rather, the three animals analyzed were included to confirm that radioactive labeling of OP-1 would not interfere with its osteoinductive properties.…”

Section: Methodsmentioning

confidence: 99%

“…All histologic sections therefore were viewed by one individual (LC) blinded to the results of manual palpation. We selected the 35-day study period because prior investigations have shown fusions to be distinguishable from nonunions by this time [2,8].…”

Section: Methodsmentioning

confidence: 99%

125I-labeled OP-1 is Locally Retained in a Rabbit Lumbar Fusion Model

Erickson

Pierce

Simpson

et al. 2008

Clinical Orthopaedics &Amp; Related Research

Self Cite

View full text Add to dashboard Cite

Osteogenic protein-1 is evolving as a potential bone graft alternative. Surgical site retention is important to maximize local osteoinduction and to limit peripheral effects. An established rabbit lumbar posterolateral fusion model was used to evaluate the systemic distribution and pharmacokinetics of locally applied osteogenic protein-1 delivered on a collagen carrier. L5-L6 intertransverse process fusions were performed on 27 New Zealand White rabbits. Radiolabeled 125 I-osteogenic protein-1 collagen putty was implanted. At intervals, whole blood, plasma, and excreta were analyzed for radioactivity with liquid scintillation counting. Surgical site and tissue radioactivity also were assessed by quantitative whole-body autoradioluminography of animals euthanized at times ranging from 6 hours to 35 days. Animals remaining at the final time were assessed for fusion with manual palpation, radiography, and histology. Limited distribution of radioactivity was observed in the blood, plasma, and tissues apart from at the surgical site and in the urinary bladder and thyroid. The mean residence time for osteogenic protein-1 collagen putty was 10.4 ± 2.7 days. These excretion profiles and kinetic properties are similar to those described for recombinant human bone morphogenetic protein-2 in the rabbit model (mean residence times of 7.6 days and 10.2 days with different carriers).

show abstract

“…They have demonstrated the efficacy of rhBMP-2 and OP-1 as bone substitutes for autografts, resulting in more rapid and reliable healing than that observed in control groups using various carrier matrices in both anterior and posterolateral spinal fusion in nonhuman primate, sheep, and rabbit models [9,11,12,15,38,46,75].…”

Section: Osteoinductive Growth Factorsmentioning

confidence: 99%

“…In an animal study, another major rhBMP, OP-1, was tested in noninstrumented posterolateral fusions and demonstrated high fusion rates [15,38,46,75]. Johnsson et al performed a randomized clinical trial for ensuring OP-1 efficacy in noninstrumented posterolateral fusion as evaluated by radiostereometric analysis.…”

Section: Grade Of Recommendationmentioning

confidence: 99%

An update on bone substitutes for spinal fusion

et al. 2009

View full text Add to dashboard Cite

With the current advances in spinal surgery, an understanding of the precise biological mechanism of each bone substitute is necessary for inducing successful spinal fusion. In this review, the categories of bone substitutes include allografts, ceramics, demineralized bone matrix, osteoinductive factors, autogenous platelet concentrate, mesenchymal stem cells, and gene therapy. Further, clinical studies have been evaluated by their levels of evidence in order to elucidate the precise effect of the bone substitute employed and to establish clinical guidance. This article will review both clinical studies based on evidence and basic research in current advances in order to avoid as far as possible any chances of failure in the future and to understand cellular biology in novel technologies.

show abstract

Evaluation of OP-1 as a Graft Substitute for Intertransverse Process Lumbar Fusion

Abstract: OP-1 was found to reliably induce solid intertransverse process fusion in a rabbit model at 5 weeks.

Cited by 162 publications

References 17 publications

Spinal fusion using an autologous growth factor gel and a porous resorbable ceramic

Spinal fusion using an autologous growth factor gel and a porous resorbable ceramic

125I-labeled OP-1 is Locally Retained in a Rabbit Lumbar Fusion Model

An update on bone substitutes for spinal fusion

Contact Info

Product

Resources

About